NCE-1 Intelligence & Market Opportunity

Avmapki Fakzynja Co-Pack

Avutometinib And Defactinib

Anticancer

Oral Capsule And Tablet

Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.

Approval Date

08-May-25

NCE-1 Date

08-May-29

NCE Date

08-May-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

93.77%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

115

2027

214

2028

338

2029

437

2030

523

2031

443

2032

475

Molecule profile

Details & specifications

Molecule

Avutometinib And Defactinib

Innovator

VERASTEM INC

Dosage Form

Oral Capsule And Tablet

Strength

EQ 0.8 mg base; EQ 200 mg base

Therapeutic Category

Anticancer

Usage

To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets